Broad-spectrum antibiotics alter the microbiome, increase intestinal fxr, and decrease hepatic steatosis in zebrafish...

Area of Science:

• Gastroenterology
• Microbiology
• Hepatology

Background:

• Short bowel syndrome (SBS) involves gut microbiome changes, inflammation, and liver disease (IFALD).
• Patients often have a history of abdominal issues and broad-spectrum antibiotic use.
• Zebrafish models can mimic human SBS complications.

Purpose of the Study:

• To investigate if antibiotics in SBS zebrafish replicate human systemic effects.
• To identify druggable targets for managing SBS and IFALD.
• To explore antibiotic impact on gut microbiome and liver health in SBS.

Main Methods:

• Administered broad-spectrum antibiotics to zebrafish with SBS.
• Analyzed changes in microbiome diversity and composition.
• Measured gene expression (tlr4, fxr, cyp7a1) and hepatic steatosis.

Main Results:

• Antibiotics altered the microbiome, decreasing diversity.
• Reduced intestinal and hepatic inflammation was observed.
• Hepatic steatosis development was decreased, with altered gene expression.

Conclusions:

• Antibiotic administration in SBS zebrafish created distinct states regarding liver fat accumulation.
• This model offers insights into managing SBS and IFALD.
• Findings suggest potential therapeutic avenues targeting microbiome and inflammation.